Boston Scientific (NYSE:BSX) and the University of Alabama settled a patent dispute over cardiac rhythm management technology.
The spat spans back to 2014, when the University of Alabama at Birmingham and the UAB Research Foundation filed a lawsuit against Boston Scientific and Cardiac Pacemakers, saying that the companies infringed on its patent by making, using, offering and selling cardiac resynchronization therapy defibrillators.
The suit was stayed in August 2015 while Boston Scientific pursued inter partes review with the U.S. Patent & Trademark office, Boston Scientific said last week in a regulatory filing. Those requests were rejected in September and October of that year, but the PTO granted a reconsideration motion request in March.
Marlborough, Mass.-based Boston Scientific said in the filing that the parties agreed to settle the case Oct. 6, but did not provide any details. Magistrate judge Staci Cornelius of the U.S. District Court for Northern Alabama dismissed the case with prejudice Oct. 19, according to court documents.
